Gedatolisib Regimens Significantly Extend Survival in Advanced Breast Cancer -

The INTERCEPT CRC study showed that clearing circulating tumor DNA (ctDNA) after adjuvant therapy is a powerful indicator of better outcomes in patients with resectable stage I–IV colorectal cancer. Researchers found that among patients who were ctDNA-positive after surgery, 26% achieved ctDNA clearance following adjuvant treatment. These patients had significantly longer disease-free survival compared to

Clearing ctDNA After Therapy Linked to Longer Survival in Colorectal Cancer Read More »

Montanide ISA-51 Emerges as a Key Adjuvant, Driving Success in Therapeutic Cancer Vaccine Trials

Suppressor Cells Linked to Bladder Cancer Progression and Treatment Resistance

Leave a Comment / Research Advances / li001

Bladder cancer (BCa) is classified by tumor spread: non-muscle invasive (~75%), muscle-invasive (~20%), and metastatic (~5%). Non-muscle invasive BCa is treated with transurethral resection (TURBT), often followed by a single chemotherapy dose for low-risk cases or Bacillus Calmette–Guérin (BCG) immunotherapy for higher-risk patients. BCG can cause toxicity and recurrence remains high. Muscle-invasive disease is treated

Suppressor Cells Linked to Bladder Cancer Progression and Treatment Resistance Read More »

Nanotechnology Paves the Way for Next-Generation Skin Cancer Treatments

Leave a Comment / Technology Innovation / li001

Skin cancer includes melanoma (MSC) and non-melanoma types (NMSC) such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Melanoma is less common but more deadly, with about 324,000 new cases and 57,000 deaths annually. NMSCs are far more common, especially BCC, though SCC causes most related deaths. Conventional treatments like surgery, radiation, chemotherapy,

Nanotechnology Paves the Way for Next-Generation Skin Cancer Treatments Read More »

Cadonilimab Plus Chemotherapy Extends Survival in Advanced Gastric and GEJ Cancer, Phase 3 Trial Confirms

FDA Approves Y-90 Microspheres for Unresectable Liver Cancer with 98.5% Response Rate

Leave a Comment / Drug Approvals / li001

The FDA has approved SIR-Spheres Y-90 resin microspheres for treating patients with unresectable hepatocellular carcinoma (HCC) who meet specific clinical criteria, such as no macrovascular invasion, Child-Pugh A cirrhosis, and well-compensated liver function. The approval is supported by the DOORwaY90 study, a multicenter trial evaluating Y-90 as a first-line therapy for unresectable HCC. Results were

FDA Approves Y-90 Microspheres for Unresectable Liver Cancer with 98.5% Response Rate Read More »

Scientists Uncover RNA-Driven Mechanism Behind Rare Kidney Cancer

Research Advances / li001

Scientists have uncovered how a rare and aggressive kidney cancer, translocation renal cell carcinoma (tRCC), develops. This cancer, mainly affecting children and young adults, is caused by abnormal hybrid genes called TFE3 oncofusions. These genes hijack the cell’s machinery to form liquid-like structures, or “droplet hubs,” inside the nucleus. RNA, instead of only carrying genetic

Scientists Uncover RNA-Driven Mechanism Behind Rare Kidney Cancer Read More »

li001